Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38

Read the full 304 word article

User Sign In